Accessibility StatementSkip Navigation Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. Orascoveryâ"¢ is an innovative oral drug delivery proprietary platform owned by Hanmi that enables the conversion of injectable medicines into oral formulations. Encequidar is a P-gp inhibitor that was discovered through Hanmi's Orascoveryâ"¢ platform and originally developed by Hanmi. Under this agreement, Hanmi and HHP will grant Gilead exclusive global rights to Enc ...